Reach Our Mammalian Experts:

mammalian@lonza.com

As one of the frontrunners in the contract manufacture of monoclonal antibodies (mAbs) and recombinant proteins from mammalian cell culture, Lonza produces the essential ingredients for tomorrow’s life-saving medicines in four state-of-the-art cGMP multi-product facilities. Our customers range from international pharmaceutical companies and large biotechnology businesses to new start-ups.  At Lonza, we are prepared to meet the needs of the market and our clients to provide the best solution for your pipeline.

Lonza’s process R&D services range from vector construction and cell line development to full-scale manufacturing. These include a complete range of analytical services and regulatory support for clinical trials and in-market supply. Our customers regularly ask us to perform tailored work packages or the complete development program.   We have an expansive line of cutting edge Development Technologies available to enhance your expression process.  From early protein target risk assessment programs to our continually upgraded and highly efficient GS Gene Expression System™, we are able to achieve higher titers, while improving speed to market, safety and costs.

Our customers may request Lonza to perform the complete development program or individual work packages.   We offer a full line development and manufacturing capabilities from DNA to BLA.  In addition, we have full range of services for Antibody Drug Conjugate production. In conjunction with our Visp chemical facility, we can produce your mAb of interest and conjugate it to the drug of choice.

To learn more about our mammalian operations, please watch our presentation by Ben Locwin, PMP, MBA, Operational Excellence Manager on global material harmonization for increased effectiveness and reduced risk.

For more information on our Mammalian Biopharmaceutical facilities, visit our site pages:

Portsmouth, NH, USA

Slough, UK

Tuas, Singapore

Porriño, Spain